Laroze Partners · Guide · Healthcare & Life Sciences · September 2026

The Chief Medical Officer is one of the rare positions where a casting error is paid for immediately, in lost regulatory time, damaged trust within the medical community, and doubt established among investors. It is also one of the most difficult recruitments to conduct, because it requires combining in a single person undeniable scientific legitimacy, a business vision, and mastery of a shifting regulatory framework. This guide details what the role actually covers, how it evolves depending on the company's stage, and what the assessment of such a profile focuses on.

The context in a few figures

Why this role has become central

A healthcare company experiences a decisive shift when it moves from research to clinical development. As long as it is exploring, science is enough to carry it. As soon as it enters the clinic, it must convince authorities, recruit patients, onboard investigators, and demonstrate to investors that its program is viable. This is the moment when the Chief Medical Officer becomes indispensable.

This function is not limited to laboratories and biotechs. It has established itself across all health technology verticals, from medical devices to digital clinical research platforms, as well as telemedicine and connected health solutions. Everywhere, the same need arises: to have a legitimate medical voice, capable of speaking to peers as equals, and translating a technological promise into a demonstrable clinical benefit.

The demand is particularly strong in therapeutic areas where the requirement of proof is maximum, oncology and hematology at the forefront, but also anesthesia and sedation, rare diseases, or chronic pathologies.

What the role actually covers

The scope of a Chief Medical Officer revolves around five dimensions that feed into one another.

Medical strategy and clinical development

The CMO defines the company's medical strategy, assesses the scientific and clinical viability of the envisioned products, and builds the clinical development plan. This involves determining the optimal sequence of trials, choosing relevant evaluation criteria, and arbitrating between speed to market and the robustness of the demonstration. These choices commit several years and a considerable share of the company's capital.

Relationship with the medical community and opinion leaders

The CMO acts as the company's scientific voice to physicians, investigators, and opinion leaders. This relationship cannot be decreed; it relies on a personal reputation built through publications, speaking engagements at conferences, and actual membership in the community of the relevant pathology. A recognized CMO opens investigator sites and accelerates patient recruitment. A CMO without legitimacy meets closed doors, without anyone saying so explicitly.

Regulatory dialogue

The CMO is the medical interlocutor for authorities, whether it is the National Agency for Medicines and Health Products Safety, the European Medicines Agency, or the Food and Drug Administration. They lead the preparation of dossiers, defend methodological choices, and anticipate requests. In this area, direct experience matters more than theoretical knowledge of the texts.

Credibility with investors

During fundraising rounds as well as divestiture operations, the CMO works alongside the CEO to defend the value of the pipeline. Specialized investors evaluate the strength of a program as much through the person leading it as through the data presented. A hesitation on a methodological point in an investment committee can cost a valuation.

Contribution to the executive committee

This is the most underestimated dimension. In many digital health or medical device companies, the executive committee does not include any other healthcare professional. The CMO carries the clinical perspective alone, facing executives from technology, finance, or business backgrounds.

Their success then depends on their ability to integrate into a collective that does not share their language, to make a medical requirement heard without blocking execution, and to quickly understand the company's long-term vision to contribute to it rather than suffer it. A scientifically brilliant CMO who is unable to influence these arbitrations leaves the company moving forward without a clinical compass.

A role that changes depending on the stage of maturity

The same title covers very different realities, and this confusion explains a good portion of recruitment errors.

In an early-stage company, the CMO builds the development plan, selects the first sites, and lays the methodological foundations. The position is close to the bench and requires strong operational involvement.

In an intermediate-stage company, the scope expands to trial oversight, regulatory strategy, and opinion leader engagement. The managerial dimension appears, with clinical development, clinical operations, and pharmacovigilance teams to structure.

As commercialization approaches, the role integrates investor relations, overall regulatory coordination, and market access preparation with commercial functions. The CMO becomes a generalist executive whose specialty is medical.

Recruiting a profile calibrated for one stage in a company that finds itself at another produces rapid friction, regardless of the person's intrinsic quality.

Specificities by vertical

In biotech, scientific legitimacy in the therapeutic area takes precedence over everything else. The CMO must be a peer recognized by the investigators they will need to convince, with a track record of publications and visibility at key conferences.

In medtech, the focus shifts toward the clinical demonstration of benefit and adoption by practitioners. The CMO works on shorter cycles, with different proof requirements and continuous dialogue with the end users who are the surgeons, anesthesiologists, or relevant specialists.

In digital clinical research, the CMO guarantees the methodological validity of the proposed solutions and reassures clients who are themselves laboratories. Their credibility conditions the signing of major contracts.

In telemedicine and digital health, they oversee the safety of care pathways, the medical quality of the service, and compliance with a still-evolving regulatory framework. They are often the company's institutional guarantor in dealings with authorities and professional bodies.

The triple requirement of the profile

Three skills must coexist in the same person, and their rarity explains the difficulty of recruitment.

Medical legitimacy requires a medical degree, often completed with a PhD, real expertise in the company's therapeutic area, and peer recognition that cannot be bought.

Business vision involves understanding an economic model, knowing how to balance scientific rigor with cash constraints, and dialoguing with investors in their language.

Mastery of the legal framework covers clinical trial regulation, pharmacovigilance obligations, promotion rules, and national specificities of market access.

Most candidates excel in one dimension, a few in two. Profiles that combine all three are few and far between, rarely actively looking, and are found through direct approach.

The French field, a special place

France occupies a unique position that makes these recruitments strategic for both French companies and foreign groups establishing themselves there.

The country participates in 53% of European clinical trials and maintains its third-place European ranking, with a second place in oncology that reflects the excellence of its centers and teams. This position makes France a sought-after demonstration ground, where a validation obtained gains international reference value.

This excellence is accompanied by real complexity. Around 160 days are still required to start a clinical trial in the country, and 94% of trials conducted in France are international, meaning that each country competes with others to secure patients and sites. An accelerated authorization system was launched in 2026 as part of France 2030, and the European FAST-EU mechanism is set to reduce delays for multinational trials.

In this context, the Chief Medical Officer of a subsidiary or a French company plays a decisive role. It is they who get investigator sites to prioritize their protocol over another, and this ability relies as much on their personal relationships as on the quality of the program.

For a foreign company setting up operations, this recruitment is often the first act of its local credibility. A CMO anchored in the French ecosystem opens doors in a few months that an organization without a medical face would take years to reach.

Why these profiles are difficult to assess

Evaluating a Chief Medical Officer cannot be reduced to checking a career path. Qualifications, publications, and positions held are easily verified, and they do not predict success.

What sets candidates apart lies elsewhere. The quality of clinical judgment under constraint, when data is incomplete and the decision commits years of development. Resilience in the face of trial failure, a statistically probable event in any trajectory. The ability to defend a position before an authority without rigidity, and before an executive committee without compromise. Finally, the aptitude to function in an organization whose culture is not medical.

These dimensions cannot be read on a curriculum vitae, and they resist conventional interviews, where an experienced candidate knows how to present their career in the best light.

Our approach: a dual perspective

It is precisely for these situations that we developed the Laroze Pattern, the firm's proprietary assessment method, which is based on a simple principle: a single perspective is not enough to evaluate an executive for this type of role.

The first perspective is that of the executive search consultant. It validates professional substance through an interview flow designed for the role, which prioritizes situational scenarios rather than a career narrative. The candidate is confronted with real problems comparable to those they will face: a disputed methodological arbitration, a relationship with an investigator becoming tense, a position to defend before a committee that does not share their priorities. The way they reason aloud says more than the description of past successes.

The second perspective is that of a psychologist expert in behavioral disorders, with whom we work on the candidates selected at the end of the process. They produce in-depth profiling that sheds light on how the person operates under pressure, their way of relating to others, their decision-making drivers, and their real compatibility with the existing leadership team.

The comparison of these two readings constitutes the value of the method. It allows us to give an opinion not only on a candidate's competence, but on their fit with a specific context, which is exactly the question raised by recruiting a Chief Medical Officer.

The most frequent casting errors

Three configurations regularly recur and deserve to be anticipated.

The first is recruiting an undeniable academic authority, whose expertise is universally recognized, but who has never worked in a corporate setting and late in the day discovers the constraints of time, budget, and trade-offs that structure a company's life.

The second is prioritizing an experienced industry profile, seasoned in the processes of a large laboratory, who turns out to be unable to operate in the uncertainty and frugality of a growing structure.

The third, more discreet, concerns compatibility with the executive committee. A CMO who does not find their place in a non-medical collective gradually becomes isolated, and the company finds itself with clinical expertise that it no longer leverages.

Frequently Asked Questions

What is the role of a Chief Medical Officer? The role of a Chief Medical Officer is to define and champion the medical strategy of a healthcare company. They build the clinical development plan, oversee trials, dialogue with regulatory authorities, represent the company to the medical community and opinion leaders, and bring the clinical perspective to the executive committee.

What is the difference between a Chief Medical Officer and a medical director? The difference between a Chief Medical Officer and a medical director lies in the level of responsibility and scope. The medical director leads a function, often medical affairs or clinical development, while the Chief Medical Officer sits on the executive committee, contributes to the overall strategy of the company, and commits their medical credibility to authorities, investors, and peers.

Do you have to be a doctor to become a Chief Medical Officer? You must be a physician to hold a Chief Medical Officer role, as the legitimacy of the function relies on the ability to speak to peers and authorities as a practitioner. A PhD in science frequently complements this education, and recognized expertise in the company's therapeutic area is generally expected.

When should a biotech recruit its first Chief Medical Officer? A biotech should recruit its first Chief Medical Officer when it transitions from research to clinical development, ideally ahead of filing the first trial application. Recruiting too late exposes the company to poorly calibrated methodological choices that become costly to correct.

How long does it take to recruit a Chief Medical Officer? Recruiting a Chief Medical Officer generally takes between three and five months, a longer timeframe than for other executive roles due to the scarcity of the talent pool and the requirement of expertise in a specific therapeutic area. Added to this is often a long notice period for profiles in office.

Can a foreign company recruit a Chief Medical Officer in France before establishing itself there? A foreign company can recruit a Chief Medical Officer in France even before having a full structure there, and this choice is common. This profile then becomes the company's first medical face in the country, opens access to investigator sites and opinion leaders, and secures dialogue with French authorities from the earliest stages.

Key Takeaways

The Chief Medical Officer is the function through which a healthcare company becomes credible in the eyes of those who decide its future: authorities, investigators, opinion leaders, and investors. Their success depends on a rare combination of medical legitimacy, business vision, and regulatory mastery, to which is added an ability to integrate into a leadership collective that is not always composed of healthcare professionals.

These profiles exist, but they are few, rarely available, and difficult to evaluate based on visible criteria alone. Identifying them requires an intimate knowledge of the medical and scientific ecosystem. Evaluating them requires a method that goes beyond the career path, down to the way a person decides, resists, and cooperates.

Laroze Partners: Executive search firm, Healthcare & Life Sciences. Executive recruitment, succession planning, and leadership team onboarding, in France and internationally. Missions guaranteed throughout the probationary period.

Sources: Leem, France's Attractiveness for Clinical Research survey, 15th edition, May 2026 · France 2030 · sector publications on the role of Chief Medical Officer in biotechnology and medical devices. This article reflects the practitioner's view of Laroze Partners.